Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/s41564-020-0695-z
10.1038/s41564-020-0695-z · External reference
Properties of Coronavirus and SARS-CoV-2
2020 · External reference
The COVID-19 epidemic
10.1111/tmi.13383 · 2020 · External reference
10.1111/jcmm.15364
10.1111/jcmm.15364 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Strategies for targeting SARS CoV-2: small molecule inhibitors-the current status
10.3389/fimmu.2020.552925 · 2020 · External reference
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
2021 · External reference
10.1016/j.phrs.2020.104859
10.1016/j.phrs.2020.104859 · External reference
Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum
10.1016/j.jpba.2021.113935 · 2021 · External reference
10.1101/2021.06.17.21258639
10.1101/2021.06.17.21258639 · External reference
A minireview of the promising drugs and vaccines in pipeline for the treatment of COVID-19 and current update on clinical trials
10.3389/fmolb.2021.637378 · 2021 · External reference
10.1038/s41564-021-00954-4
10.1038/s41564-021-00954-4 · External reference
10.1016/j.cell.2021.06.020
10.1016/j.cell.2021.06.020 · External reference
10.1016/j.jsb.2010.11.021
10.1016/j.jsb.2010.11.021 · External reference
10.3390/v6082991
10.3390/v6082991 · External reference
10.1186/s12985-019-1182-0
10.1186/s12985-019-1182-0 · External reference
10.1128/jvi.78.19.10328-10335.2004
10.1128/jvi.78.19.10328-10335.2004 · External reference
10.3390/v4061011
10.3390/v4061011 · External reference
10.1038/s41392-021-00809-8
10.1038/s41392-021-00809-8 · External reference
10.1038/s41598-020-71748-7
10.1038/s41598-020-71748-7 · External reference
10.1038/s41467-020-16567-0
10.1038/s41467-020-16567-0 · External reference
10.1016/j.cell.2020.02.058
10.1016/j.cell.2020.02.058 · External reference
10.1007/s00109-021-02092-0
10.1007/s00109-021-02092-0 · External reference
10.1038/nature02145
10.1038/nature02145 · External reference
Recent developments on therapeutic and diagnostic approaches for COVID-19
10.1208/s12248-020-00532-2 · 2021 · External reference
10.1038/s42255-020-00324-0
10.1038/s42255-020-00324-0 · External reference
SARS-CoV-2 receptor ACE2 is co-expressed with genes related to transmembrane serine proteases, viral entry, immunity and cellular stress
10.1038/s41598-020-78402-2 · 2020 · External reference
Comparison of severe acute respiratory syndrome coronavirus 2 spike protein binding to ACE2 receptors from human, pets, farm animals, and putative intermediate hosts
10.1128/jvi.00831-20 · 2020 · External reference
10.1073/pnas.2003138117
10.1073/pnas.2003138117 · External reference
10.1128/jvi.73.1.177-185.1999
10.1128/jvi.73.1.177-185.1999 · External reference
Characterization of a human coronavirus (strain 229E) 3C-like proteinase activity
10.1128/jvi.69.7.4331-4338.1995 · 1995 · External reference
10.1128/jvi.78.24.13600-13612.2004
10.1128/jvi.78.24.13600-13612.2004 · External reference
SARS-CoV-2: structure biology, and structure-based therapeutics development
10.3389/fcimb.2020.587269 · 2020 · External reference
10.1038/s41586-020-2368-8
10.1038/s41586-020-2368-8 · External reference
Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein
2021 · External reference
10.1038/s41467-020-17796-z
10.1038/s41467-020-17796-z · External reference
10.2337/dbi20-0019
10.2337/dbi20-0019 · External reference
10.1016/j.virol.2015.08.010
10.1016/j.virol.2015.08.010 · External reference
10.1016/j.it.2020.10.004
10.1016/j.it.2020.10.004 · External reference
SARS-CoV-2 infection in alpha1-antitrypsin deficiency
10.1016/j.rmed.2021.106466 · 2021 · External reference
10.1016/s2213-2600(21)00018-7
10.1016/s2213-2600(21)00018-7 · External reference
Alpha-1 antitrypsin deficiency severity and the risk of COVID-19: a Portuguese cohort
10.1016/j.rmed.2021.106387 · 2021 · External reference
Unresolved reference
External reference
Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2
10.1038/s41598-021-83229-6 · 2021 · External reference
10.1101/2021.03.22.436522
10.1101/2021.03.22.436522 · External reference
10.3390/molecules20010573
10.3390/molecules20010573 · External reference
10.1007/s002800100367
10.1007/s002800100367 · External reference
10.1016/j.ejim.2020.04.037
10.1016/j.ejim.2020.04.037 · External reference
10.1038/s12276-021-00624-9
10.1038/s12276-021-00624-9 · External reference
10.1038/s41422-020-0305-x
10.1038/s41422-020-0305-x · External reference
Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19: results from a randomized, double-blinded, placebo-controlled trial
2021 · External reference
Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies
10.1038/s41598-021-81462-7 · 2021 · External reference
10.1038/s41598-021-89957-z
10.1038/s41598-021-89957-z · External reference
10.1016/j.cell.2021.06.002
10.1016/j.cell.2021.06.002 · External reference
10.1101/2021.06.14.21258569
10.1101/2021.06.14.21258569 · External reference
A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants
10.1038/s41467-021-25331-x · 2021 · External reference
10.3390/molecules26051200
10.3390/molecules26051200 · External reference
A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication
10.1038/s41467-021-20900-6 · 2021 · External reference
Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model
10.1038/s41598-021-89013-w · 2021 · External reference
A review on Remdesivir: a possible promising agent for the treatment of COVID-19
10.2147/dddt.s261154 · 2020 · External reference
Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19
10.1002/phar.2429 · 2020 · External reference
10.1038/s41467-020-20542-0
10.1038/s41467-020-20542-0 · External reference
Remdesivir in the treatment of COVID-19
10.1097/01.naj.0000731668.01845.8c · 2021 · External reference
10.1056/nejmoa2007764
10.1056/nejmoa2007764 · External reference
SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective
10.1080/07391102.2020.1761882 · 2021 · External reference
Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study
10.1016/j.lfs.2020.117592 · 2020 · External reference
Unresolved reference
External reference
10.1016/j.jmgm.2021.108042
10.1016/j.jmgm.2021.108042 · External reference
Unresolved reference
External reference
10.3390/molecules26195795
10.3390/molecules26195795 · External reference
10.1093/infdis/jiab247
10.1093/infdis/jiab247 · External reference
Abbreviated Profile of Drugs (APOD): modeling drug safety profiles to prioritize investigational COVID-19 treatments
10.1016/j.heliyon.2021.e07666 · 2021 · External reference
Oseltamivir treatment prevents the increased influenza virus disease severity and lethality occurring in chronic ethanol consuming mice
10.1111/j.1530-0277.2010.01226.x · 2010 · External reference
10.1016/j.bioorg.2020.104257
10.1016/j.bioorg.2020.104257 · External reference
Syncytia formation by SARS-CoV-2-infected cells
10.15252/embj.2020106267 · 2020 · External reference
10.1038/s41418-021-00782-3
10.1038/s41418-021-00782-3 · External reference
10.1038/s41586-021-03491-6
10.1038/s41586-021-03491-6 · External reference
10.1016/j.amsu.2021.102779
10.1016/j.amsu.2021.102779 · External reference
Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19
2020 · External reference
10.1111/j.1365-2249.2004.02415.x
10.1111/j.1365-2249.2004.02415.x · External reference
10.1371/journal.ppat.1000756
10.1371/journal.ppat.1000756 · External reference
Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza
10.1086/656044 · 2010 · External reference
10.3389/fimmu.2020.01708
10.3389/fimmu.2020.01708 · External reference
10.1016/j.intimp.2020.107225
10.1016/j.intimp.2020.107225 · External reference
10.3389/fimmu.2020.01446
10.3389/fimmu.2020.01446 · External reference
novel coronavirus in Wuhan, China
2019 · External reference
10.1093/cid/ciaa449
10.1093/cid/ciaa449 · External reference
Tocilizumab: the first interleukin-6-receptor inhibitor
10.2146/ajhp070449 · 2008 · External reference
Effective treatment of severe COVID-19 patients with tocilizumab
10.1073/pnas.2005615117 · 2020 · External reference
Tocivid-19 investigators, Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
10.1186/s12967-020-02573-9 · 2020 · External reference
COVID-19: Still a place for tocilizumab?
2021 · External reference
Unresolved reference
External reference
10.1016/s2665-9913(20)30164-8
10.1016/s2665-9913(20)30164-8 · External reference
The effect of anakinra in hospitalized patients with COVID-19: an updated systematic review and meta-analysis
10.3390/jcm10194462 · 2021 · External reference
Effects of chloroquine on viral infections: an old drug against today's diseases?
10.1016/s1473-3099(03)00806-5 · 2003 · External reference
COVID-19: Cytokine storm modulation/blockade with oral polyvalent immunoglobulins (PVIG, KMP01D): A potential and safe therapeutic agent (Primum nil nocere)
10.5414/cp203890 · 2020 · External reference
Impact of hydroxychloroquine/chloroquine in COVID-19 therapy: two sides of the coin
10.1089/jir.2020.0105 · 2020 · External reference
A randomized, controlled trial
10.1093/cid/ciaa1009 · 2019 · External reference
Pharmacology and adverse events of emergency-use authorized medication in moderate to severe COVID-19
10.3390/ph14100955 · 2021 · External reference
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context, Lancet
2021 · External reference
A comprehensive review on sarilumab in COVID-19
10.1080/14712598.2021.1847269 · 2021 · External reference
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
10.1136/jitc-2020-001089 · 2020 · External reference
10.4161/mabs.2.1.10328 · Admitted local publication
Canakinumab as treatment for COVID-19-related pneumonia: a prospective case-control study
10.1016/j.ijid.2020.12.073 · 2021 · External reference
Efficacy of canakinumab in mild or severe COVID-19 pneumonia
10.1002/iid3.400 · 2021 · External reference
Interleukin 18 (IL-18) as a target for immune intervention
10.18388/abp.2015_1153 · 2016 · External reference
10.1016/j.cell.2020.11.025
10.1016/j.cell.2020.11.025 · External reference
Longitudinal characterization of cytokine overproduction: a case report in critically ill COVID-19 patients with hyperinflammation in bronchoalveolar lavage
2021 · External reference
Cytokine storm intervention in the early stages of COVID-19 pneumonia
10.1016/j.cytogfr.2020.04.002 · 2020 · External reference
10.1016/s0140-6736(20)30317-2
10.1016/s0140-6736(20)30317-2 · External reference
10.1371/journal.pone.0032777
10.1371/journal.pone.0032777 · External reference
Object class segmentation of RGB-D video using recurrent convolutional neural networks
10.1016/j.neunet.2017.01.003 · 2017 · External reference
10.1016/s1473-3099(20)30132-8
10.1016/s1473-3099(20)30132-8 · External reference
Use of MRI for personalized treatment of more aggressive tumors
10.1148/radiol.2020200678 · 2020 · External reference
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
10.1016/j.jinf.2020.06.052 · 2020 · External reference
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial
10.1016/j.jaci.2020.05.019 · 2020 · External reference
10.1016/s0140-6736(20)30304-4
10.1016/s0140-6736(20)30304-4 · External reference
10.1056/nejmoa2031994
10.1056/nejmoa2031994 · External reference
10.1101/cshperspect.a001651
10.1101/cshperspect.a001651 · External reference
Targeting NF-kappaB pathway for the therapy of diseases: mechanism and clinical study
10.1038/s41392-020-00312-6 · 2020 · External reference
Intestinal transcriptome analysis reveals soy derivative-linked changes in atlantic salmon
10.3389/fimmu.2020.596514 · 2020 · External reference
10.1128/jvi.02576-13
10.1128/jvi.02576-13 · External reference
10.1016/j.virusres.2007.02.007
10.1016/j.virusres.2007.02.007 · External reference
An immunomodulatory herbal extract with potent antiviral activity against SARS-CoV-2
10.1371/journal.pone.0241739 · 2020 · External reference
Discovery of novel pyrazole derivatives as a potent anti-inflammatory agent in RAW264.7 cells via inhibition of NF-kB for possible benefit against SARS-CoV-2
10.1002/jbt.22656 · 2021 · External reference
in a 2019-novel coronavirus-related coronavirus model
2019 · External reference
Cepharanthine suppresses herpes simplex virus type 1 replication through the downregulation of the PI3K/Akt and p38 MAPK signaling pathways
10.3389/fmicb.2021.795756 · 2021 · External reference
Small molecule screening identified cepharanthine as an inhibitor of porcine reproductive and respiratory syndrome virus infection in vitro by suppressing integrins/ILK/RACK1/PKCalpha/NF-kappaB signalling axis
10.1016/j.vetmic.2021.109016 · 2021 · External reference
Cepharanthine: an update of its mode of action, pharmacological properties and medical applications
10.1016/j.phymed.2019.152956 · 2019 · External reference
10.1016/j.isci.2021.102367
10.1016/j.isci.2021.102367 · External reference
10.1007/s43440-020-00132-z
10.1007/s43440-020-00132-z · External reference
Pidotimod: a reappraisal
10.1177/039463200902200201 · 2009 · External reference
Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression
10.1186/1824-7288-39-29 · 2013 · External reference
Immunostimulants in respiratory diseases: focus on Pidotimod
10.4081/mrm.2019.50 · 2019 · External reference
Pidotimod: In-depth review of current evidence
10.4103/lungindia.lungindia_39_19 · 2019 · External reference
Pidotimod in paucisymptomatic SARS-CoV2 infected patients
10.4084/mjhid.2020.048 · 2020 · External reference
10.1007/s10753-020-01337-3
10.1007/s10753-020-01337-3 · External reference
Saudi critical care trial, corticosteroid therapy for critically ill patients with middle east respiratory syndrome
10.1164/rccm.201706-1172oc · 2018 · External reference
Long-term systemic corticosteroid exposure: a systematic literature review
10.1016/j.clinthera.2017.09.011 · 2017 · External reference
10.1038/s41375-020-0848-3
10.1038/s41375-020-0848-3 · External reference
The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis
10.1186/s13054-019-2395-8 · 2019 · External reference
Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis
10.1001/jama.2020.17023 · 2020 · External reference
10.1186/s13054-017-1659-4
10.1186/s13054-017-1659-4 · External reference
Dexamethasone in Hospitalized Patients with Covid-19
10.1056/nejmoa2021436 · 2021 · External reference
10.1001/jama.2020.17021
10.1001/jama.2020.17021 · External reference
Unresolved reference
External reference
10.1111/all.14595
10.1111/all.14595 · External reference
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study
10.1093/rheumatology/keaa587 · 2021 · External reference
10.1016/j.autrev.2020.102554
10.1016/j.autrev.2020.102554 · External reference
10.1016/j.apsb.2020.06.002
10.1016/j.apsb.2020.06.002 · External reference
Traditional Chinese medicine as an adjunctive therapy for mild and common COVID-19: a systematic review and network meta-analysis
10.1097/md.0000000000027372 · 2021 · External reference
Reflections on treatment of COVID-19 with traditional Chinese medicine
10.1186/s13020-020-00375-1 · 2020 · External reference
10.1097/cm9.0000000000000819
10.1097/cm9.0000000000000819 · External reference
10.1016/j.pharmthera.2021.107843
10.1016/j.pharmthera.2021.107843 · External reference
Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
10.1016/j.phrs.2020.104761 · 2020 · External reference
Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019
10.1016/j.phrs.2020.105036 · 2020 · External reference
Total Face Approach (TFA): a novel 3D approach to describe the main cephalometric craniomaxillofacial parameters
10.3390/mps4010015 · 2021 · External reference
Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients
2020 · External reference
Chinese medicine formula huashibaidu granule early treatment for mild COVID-19 patients: an unblinded, cluster-randomized clinical trial
10.3389/fmed.2021.696976 · 2021 · External reference
XueBiJing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial
10.1097/ccm.0000000000003842 · 2019 · External reference
Xuebijing Ameliorates Sepsis-Induced Lung Injury by Downregulating HMGB1 and RAGE Expressions in Mice
2015 · External reference
Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: A meta-analysis of randomized controlled trials
10.1016/j.jep.2018.05.043 · 2018 · External reference
10.3390/vaccines9101195
10.3390/vaccines9101195 · External reference
10.1080/14760584.2021.1976153
10.1080/14760584.2021.1976153 · External reference
Unresolved reference
External reference
10.1002/jmv.27541
10.1002/jmv.27541 · External reference
10.1021/acs.jcim.1c01451
10.1021/acs.jcim.1c01451 · External reference
Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection
10.1073/pnas.2101555118 · 2021 · External reference
10.1016/j.chom.2021.04.007
10.1016/j.chom.2021.04.007 · External reference
Unresolved reference
External reference
10.1038/s41467-021-24963-3
10.1038/s41467-021-24963-3 · External reference
10.1016/j.cell.2021.03.028
10.1016/j.cell.2021.03.028 · External reference
10.3390/genes12071061
10.3390/genes12071061 · External reference
Insights into SARS-CoV-2’s mutations for evading human antibodies: sacrifice and survival
2021 · External reference
10.1016/j.cell.2021.04.025
10.1016/j.cell.2021.04.025 · External reference
10.1038/s41579-021-00573-0
10.1038/s41579-021-00573-0 · External reference
10.1016/j.xcrm.2021.100255
10.1016/j.xcrm.2021.100255 · External reference
10.1038/s41586-021-03777-9
10.1038/s41586-021-03777-9 · External reference
10.1101/2021.08.12.456173
10.1101/2021.08.12.456173 · External reference
10.1016/j.bioorg.2020.104269
10.1016/j.bioorg.2020.104269 · External reference
10.1073/pnas.1811345115
10.1073/pnas.1811345115 · External reference
10.1186/s12967-020-02344-6
10.1186/s12967-020-02344-6 · External reference
RdRp mutations are associated with SARS-CoV-2 genome evolution
10.7717/peerj.9587 · 2020 · External reference
SARS-CoV-2 genetic variations associated with COVID-19 pathogenicity
2021 · External reference
Mutational spectra of SARS-CoV-2 orf1ab polyprotein and signature mutations in the United States of America
10.1002/jmv.26417 · 2021 · External reference
Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics
10.1186/s43141-021-00152-z · 2021 · External reference
10.1016/j.biopha.2021.111330
10.1016/j.biopha.2021.111330 · External reference
10.1038/s41586-021-03398-2
10.1038/s41586-021-03398-2 · External reference
SARS-CoV-2 mutations: the biological trackway towards viral fitness
10.1017/s0950268821001060 · 2021 · External reference
Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies
2021 · External reference
Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective
10.7150/ijbs.45538 · 2020 · External reference
10.1016/j.virusres.2004.11.004
10.1016/j.virusres.2004.11.004 · External reference
10.1038/s41467-020-19706-9
10.1038/s41467-020-19706-9 · External reference
10.1007/s11427-020-1643-8
10.1007/s11427-020-1643-8 · External reference
Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test
10.1002/jmv.25930 · 2020 · External reference
Role of monoclonal antibody drugs in the treatment of COVID-19
10.12998/wjcc.v8.i19.4280 · 2020 · External reference
Mechanical ventilation: state of the art
10.1016/j.mayocp.2017.05.004 · 2017 · External reference
